Genentech Inc. and Hoffmann-La Roche Inc. have initiated a comprehensive patent infringement lawsuit concerning a proposed biosimilar of Perjeta, a key therapeutic agent for HER2-positive breast cancer. The legal action underscores the ongoing tension between originator pharmaceutical companies and biosimilar manufacturers over intellectual property rights.
Perjeta, known generically as pertuzumab, is a monoclonal antibody that targets the HER2 receptor, playing a crucial role in the treatment of HER2-positive breast cancer. The drug was first approved by the U.S. Food and Drug Administration in 2012 and has since become a significant component of combination therapies for this aggressive cancer subtype. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Pertuzumab?utm_source=openai))
The current lawsuit is part of a broader pattern of legal disputes involving Genentech and Roche as they seek to protect their patent portfolios from biosimilar competition. In March 2025, Roche settled a patent lawsuit with the University of Pennsylvania, which had accused the company of infringing a now-expired patent related to cancer treatments. The settlement was reached just weeks before a jury trial was scheduled to commence. ([news.bloomberglaw.com](https://news.bloomberglaw.com/health-law-and-business/penn-roche-end-patent-suit-over-cancer-drugs-worth-billions?utm_source=openai))
Similarly, in July 2023, Genentech, Roche, and Chugai Pharmaceutical Co. Ltd. filed a lawsuit against Biogen and Bio-Thera Solutions, Ltd. over a proposed biosimilar of Actemra (tocilizumab). The plaintiffs alleged that the biosimilar would infringe multiple patents related to the manufacture and use of Actemra. ([pearceip.law](https://www.pearceip.law/2023/07/13/genentech-roche-and-chugai-sue-biogen-and-bio-thera-over-actrema-tocilizumab-biosimilar/?utm_source=openai))
These legal actions highlight the pharmaceutical industry’s ongoing efforts to navigate the complex landscape of biosimilar development and patent law. As biosimilars continue to emerge as cost-effective alternatives to biologic therapies, originator companies are increasingly vigilant in defending their intellectual property rights to maintain market exclusivity.
The outcome of the current lawsuit over the Perjeta biosimilar will be closely watched by industry stakeholders, as it may set important precedents for future biosimilar litigation and the balance between innovation and competition in the biopharmaceutical sector.